TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 10, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Theravance Biopharma, Inc. ("Theravance Biopharma, Inc.") (NASDAQ: TBPH) concerning potential violations of the federal securities laws.
On the Q3 2025 earnings call (November 10, 2025), CEO Rick Winningham stated the Company was "on track to achieve near-term milestones totaling $75 million in the fourth quarter -- $50 million for Trelegy and $25 million for YUPELRI." On the Q2 2025 call (August 12, 2025), CFO Aziz Sawaf reaffirmed "all elements of our 2025 financial guidance." Neither statement addressed the possibility that a CYPRESS failure could trigger an accelerated strategic review, restructuring costs, or a fundamental reassessment of the Company's development-stage spending.
On March 3, 2026, Theravance disclosed that the CYPRESS trial failed to meet its primary endpoint and announced an accelerated strategic review, including termination of the ampreloxetine program. The stock fell approximately 26% in a single session.
If you suffered a loss on your Theravance Biopharma, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287958
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations
2026-03-10 12:09 PM EDT
Fraud Investigation Opened: Levi & Korsinsky Investigates Surgery Partners, Inc. (SGRY) on Behalf of Shareholders
2026-03-09 3:15 PM EDT
Ongoing Grocery Outlet Holding Corp. (GO) Investigation: Protect Your Rights - Contact Levi & Korsinsky
2026-03-09 1:17 PM EDT
May 30, 2025
A well-timed, well-written press release builds trust. A careless one invites scrutiny. Communicating clearly and compliantly is harder...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services